We connect science and compassion to reimagine mental health care.
COMPASS Pathways is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is developing COMP360 psilocybin therapy, currently in Phase 3 clinical trials for treatment-resistant depression, as well as studies for PTSD and anorexia nervosa. Listed on Nasdaq as CMPS, COMPASS holds FDA Breakthrough Therapy designation for its lead candidate.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountFeb 2026
Feb 2026
Jan 2025
Aug 2023
Sep 2020
Aug 2020
Apr 2020
Jan 2019
Oct 2018
Oct 2018
Jan 2017
Create a free account to see which investors have funded this company.
Create Free Account
Workforce mental health platform that uses AI-powered matching to connect employees with high-qua...
OneOncology empowers oncology practices with advanced tools and capabilities to help physicians d...
Healthcare company in Europe
Mehiläinen is a leading Finnish private healthcare company providing medical, health, and special...
Next-gen Medicare Advantage insurance plan with AI-forward medical group delivering quality and s...
Klick Health is a healthcare marketing and commercialization agency serving life sciences and pha...
